Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Elevated Z polymer levels may predict lung and liver disease activity in patients with alpha 1 ...

Beam Therapeutics Inc. BEAM shares are up during Wednesday’s premarket session following the release of promising clinical ...

Beam Therapeutics BEAM announced positive updated safety and efficacy data from a phase I/II study evaluating its pipeline ...

Alpha-1 antitrypsin deficiency, AATD, is an inherited disease affecting the lung, liver, and, rarely, skin. Alpha-1 antitrypsin, AAT, is a protease inhibitor of the proteolytic enzyme elastase.

Boosting levels of a deficient protein has clear survival benefits for people with the genetic condition alpha-1 antitrypsin deficiency (AATD), according to new research led by RCSI University of ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug designation for KB408 for the treatment of alpha-1 antitrypsin deficiency, according ...

New Data Demonstrate Proportion of Corrected M-AAT Reached a Mean of 91% of Total AAT in Circulation at Day 28 Following BEAM-302 Treatment in 60 mg Cohort (n=3) Mean Decrease of 79% in Mutant Z-AAT ...

SHANGHAI, February 19, 2026--(BUSINESS WIRE)--YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene editing therapies, today announced positive interim data from an ...

Chronic obstructive pulmonary disease (COPD) remains highly prevalent among veterans, but the contribution of alpha-1 antitrypsin deficiency (AAT deficiency or AATD) to this patient population remains ...

Prime Medicine announces promising preclinical results for a novel AATD treatment using advanced Prime Editing technology, aiming for clinical trials by mid-2026. Prime Medicine, Inc. announced the ...